Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Brophy

Neurological Surgery Memphis, TN Medical Doctor

NPI 1013930296 CMS profile 137378

6325 Humphreys Blvd, Memphis, TN 38120

Open in the dashboard

General payments

$390

22 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$8,324,021

14 holdings reported · through program year 2025

Through program year 2025, John Brophy of Memphis, TN is reported in the CMS Open Payments database as having received $390 across 22 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $8,324,021 across 14 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 20th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $251 15
2024 General $97 5
2022 General $17 1
2019 General $25 1
2025 Ownership $2,000,620 2
2024 Ownership $2,000,620 2
2023 Ownership $2,000,620 2
2022 Ownership $567,127 2
2021 Ownership $567,127 2
2020 Ownership $567,127 2
2019 Ownership $620,780 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Brophy
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to John Brophy were reported at $251. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year John Brophy Neurological Surgery median Middle half National median
2019 $25 $582 $138–$3,006 $163
2020 $0 $294 $76–$2,174 $114
2021 $0 $387 $105–$2,432 $132
2022 $17 $542 $139–$2,989 $149
2023 $0 $534 $145–$2,697 $160
2024 $97 $574 $155–$3,046 $164
2025 $251 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $309 18 payments
  2. Portola Pharmaceuticals, Inc. $25 1 payment
  3. AbbVie, Inc. $24 1 payment
  4. Biohaven Pharmaceutical Holding Company Ltd. $17 1 payment
  5. Medtronic, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $390 22 payments
Products named General payments · program years 2019–2025
  1. WaveWriter Alpha Prime 16 $272 14 payments
  2. AVVIGO Guidance System $30 3 payments
  3. ANDEXXA $25 1 payment
  4. BOTOX $24 1 payment
  5. NURTEC ODT $17 1 payment
  6. INTELLIS ADAPTIVESTIM $14 1 payment
  7. ROTAPRO $7 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

292

Median for Neurosurgery: 83

Drug cost

$3,547

Median for Neurosurgery: $872

Branded share of claims

22.9%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 96 $883
Pregabalin Generic 11 $824
Piroxicam Generic 18 $595
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 36 $465
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 31 $376
Meloxicam Generic 69 $187
Methylprednisolone Generic 18 $177
Tramadol Hcl Generic 13 $39

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$76,682

Medicare's payments for the services billed

Medicare patients

255

Average age 72

Services billed

605

119 women, 136 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 37%
Ischemic heart disease 35%
Depression 22%
Chronic kidney disease 18%
Osteoporosis 15%
COPD 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

22 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record